Evidence map›Paper›PMID 23603435›Full record

ReviewCancer letters2013

Novel dimensions of piRNAs in cancer.

Yuping Mei, David Clark, Li Mao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer letters, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
17.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 126 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Yuping MeiDepartment of Oncology and Diagnostic Sciences, University of Maryland School of Dentistry, Baltimore, MD 21201, USA.
David Clark
Li Mao
University of Maryland, Baltimore · US

Funding

HDGF: a novel biomarker and therapetic target of lung cancerR01CA126818 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MAO, LI · 2008 to 2012
$1.6M
ROLE OF DNA METHYLTRANSFERASE 3B IN LUNG TUMORIGENESISR01CA136635 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI MAO, LI · 2009 to 2014
$1.5M
NCI NIH HHS R01 CA126818NCI NIH HHS R01 CA136635
6 · The paper itself

Abstract

Piwi-interacting RNAs (piRNAs), a newly identified class of small non-coding RNAs, direct the Piwi-dependent transposon silencing, heterochromatin modification and germ cell maintenance. Owing to our limited knowledge regarding their biogenesis, piRNAs are considered as the most mysterious class of small regulatory RNAs, particularly in pathogenesis such as tumorigenesis. Recently, several lines of evidence have emerged to suggest that piRNAs may be dis-regulated and play crucial roles in tumorigenesis in previously unsuspected ways. In this prospective piece, we will discuss the emerging insights into the potential novel roles of piRNAs in carcinogenesis and highlight their potential implications in cancer detection, classification and therapy.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsApoptosisBiomarkers, TumorEpigenesis, GeneticHumansNeoplasm InvasivenessNeoplasm MetastasisNeoplasmsPrognosisRNA, Small InterferingTranscription, GeneticBiomarkers, TumorRNA, Small Interfering

Identifiers

PMID23603435
PMCPMC3707114
OpenAlexW2109305617

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.